抽象
外用消炎药减少嗜酸粒细胞浸润。这个动作可能是由于对负责促进嗜酸性粒细胞存活上皮细胞产品的发布效果。我们研究粒细胞/巨噬细胞集落刺激因子(GM-CSF)的释放和来自培养的鼻上皮细胞中诱导嗜酸性粒细胞的分泌物生存丙酸氟替卡松,布地奈德,二丙酸倍氯米松和奈多罗米钠的效果。人上皮细胞条件培养基(HECM)通过从经历矫正鼻部手术健康受试者获得的培养的上皮细胞产生的。从外周血中分离Normodense嗜酸性粒细胞与具有和不具有药物产生HECM中温育。所有的药物测试的抑制嗜酸性粒细胞的存活,并且反应是剂量依赖性的。丙酸氟替卡松具有最高的抑制效力(25%抑制浓度(IC25)1×10(-9)M),接着布地奈德(IC25 3.3×10(-8)M),二丙酸倍氯米松(IC25为1.5×10(-6)M),和奈多罗米钠IC25 5×10(-6)M)。同样地,氟替卡松是最强的类固醇在抑制GM-CSF的释放(IC25 8.4×10(-11)M),接着布地奈德(IC25 2×10(-9)M),二丙酸倍氯米松(IC25 13x10(-8)M),和奈多罗米钠(IC25> 10(-5)M)。 A significant correlation was found between both inhibitory effects (r=0.955; p<0.05). Topical anti-inflammatory drugs may decrease eosinophil survival by abrogating the promoting effect of epithelial cells. These drugs may exert part of their therapeutic effect by modulating GM-CSF release. The following rank of potency was observed: fluticasone propionate > budesonide > beclomethasone dipropionate > nedocromil sodium. The study of the interaction between epithelial cells and eosinophils may be a useful method for investigating and comparing the potency of topical drugs.